New Clinical Trial for Non-squamous Non-small Cell Lung Cancer

Posted by ALCF Staff on March 28th, 2017
No Comments

A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease worsened after initial response to immunotherapy. The randomized phase II study, known as HCRN LUN15-233, involves Taxotere® with or without Opdivo®. About 58 subjects will participate in the study, and will be randomized to one of two treatment arms. Arm A will receive Taxotere plus Opdivo, while Arm B will receive Opdivo alone. Eligible subjects must have advanced non-squamous non-small cell lung cancer with previous clinical benefit on treatment with single agent Opdivo. Additional criteria must be met to enroll. Learn more at

About Guneet Walia, PhD

Dr. Guneet Walia is here to serve as your guide through what can feel like an overwhelming amount of information and jargon in lung cancer research. With her extensive background in oncology & drug development in the lab and experience working with cancer patients, she culls through the latest news to bring you the most important developments that can impact you and your disease today. If you have any questions, please don't hesitate to get in touch with Dr. Walia.
Leave a Reply: